Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A little attention is paid to the AHT efficacy escaping problem, which can be explained by the AHT correction simplicity and rapid achievement of the target BP level. Nevertheless, modern statistic data on the effective AH treatment described above let us assume that AHT correction is either totally absent or is untimely in case of the "escape" phenomenon development. This could be one of the main reasons for the high prevalence of ineffective AH treatment. The aim of this study is to determine AHT efficacy "escape" phenomenon timeline and its predictors in hypertensive patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| "Escape" Phenomenon of the Antihypertensive Therapy Efficacy | Men and women aged 18-90 years with arterial hypertension grade 1-3, stage I-II and initially achieved target BP levels while taking 2-3-component AHT. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ambulatory blood pressure measurement device | Device | Assessment of the 24-h blood pressure profile |
|
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of BP increasing higher the target level when taking the same therapy | Assessment of attenuation of efficacy of previously adequate antihypertensive therapy by using different BP measurement methods | 1-6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Disease course: assessment of major CVE and death occurrence | Assessment of the disease course depending on the characteristics of 3-6th months of observation | 10 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Men and women aged 18-90 years with arterial hypertension grade 1-3, stage I-II and initially achieved target BP levels while taking 2-3-component AHT.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Oksana Mikhailova | Moscow | Russia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Sphygmocor | Device | Assessment of the arterial stiffness |
|
| VaSera-VS | Device | Assessment of the arterial stiffness |
|
| Somnocheck | Device | Assessment of the sleep breath disturbances |
|